Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on Inari Medical and raised the price target from $71 to $74, indicating positive analyst sentiment.

October 29, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has maintained a Buy rating on Inari Medical and increased the price target from $71 to $74, suggesting a positive outlook for the stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates confidence in Inari Medical's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100